Prophylactic Therapy Response in Children with Abdominal Migraine:A Single Centre Experience in Oman
10.5223/pghn.2022.25.2.121
- Author:
Tawfiq Taki AL LAWATI
1
;
Omar I. SAADAH
;
Ruwaina al RIYAMI
;
Zuwaina al YARUBI
Author Information
1. Department of Child Health, The Royal Hospital, Muscat, Oman
- Publication Type:Original Article
- From:Pediatric Gastroenterology, Hepatology & Nutrition
2022;25(2):121-128
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Abdominal migraine (AM) is a very common functional gastrointestinal disorder in children. This study reports the clinical features and response of AM to prophylactic treatment in children.
Methods:This retrospective study was conducted between January 2010 and December 2019 at the Royal Hospital in the Sultanate of Oman. This study included children aged ≤ 13 years with a diagnosis of AM based on the Rome IV criteria for functional diagnoses. Clinical, demographic, and treatment data were collected.
Results:Seventy-four children were identified, of which 43 were eligible for inclusion in this study. The median age at the onset of symptoms was 7 years (range, 2–12 years). The most frequent symptoms were headache (81.4%), nausea (79.1%), and vomiting (72.1%).Of the total cohort, 46.5%, 23.3%, and 6.9% received riboflavin, pizotifen, and propranolol monotherapy, respectively. Combination therapy was also used; 16.3% of children received pizotifen and propranolol, 4.7% received riboflavin and pizotifen, and 2.3% received riboflavin and propranolol. Patients treated with propranolol monotherapy showed 100% clinical improvement and those treated with riboflavin or pizotifen monotherapy showed 90% clinical improvement. Response to combination therapy with pizotifen and propranolol was 71.4%, and with riboflavin and pizotifen was 100%. In addition, treatment response was significantly associated with the presence of vomiting (p=0.039).
Conclusion:We found a favorable response to various modalities and combination treatments with riboflavin, pizotifen, and propranolol in children with AM. In addition, the presence of vomiting may predict treatment response.
